1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
2
|
Goldstraw P, Ball D, Jett JR, Le Chevalier
T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer.
Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
4
|
Turajlic S and Swanton C: Metastasis as an
evolutionary process. Science. 352:169–175. 2016. View Article : Google Scholar : PubMed/NCBI
|
5
|
Keating ST and El-Osta A: Transcriptional
regulation by the Set7 lysine methyltransferase. Epigenetics.
8:361–372. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Xiao B, Jing C, Wilson JR, Walker PA,
Vasisht N, Kelly G, Howell S, Taylor IA, Blackburn GM and Gamblin
SJ: Structure and catalytic mechanism of the human histone
methyltransferase SET7/9. Nature. 421:652–656. 2003. View Article : Google Scholar : PubMed/NCBI
|
7
|
Li Y, Reddy MA, Miao F, Shanmugam N, Yee
JK, Hawkins D, Ren B and Natarajan R: Role of the histone H3 lysine
4 methyltransferase, SET7/9, in the regulation of
NF-kappaB-dependent inflammatory genes. Relevance to diabetes and
inflammation. J Biol Chem. 283:26771–26781. 2008. View Article : Google Scholar : PubMed/NCBI
|
8
|
Dhayalan A, Kudithipudi S, Rathert P and
Jeltsch A: Specificity analysis-based identification of new
methylation targets of the SET7/9 protein lysine methyltransferase.
Chem Biol. 18:111–120. 2011. View Article : Google Scholar : PubMed/NCBI
|
9
|
Yang J, Huang J, Dasgupta M, Sears N,
Miyagi M, Wang B, Chance MR, Chen X, Du Y, Wang Y, et al:
Reversible methylation of promoter-bound STAT3 by histone-modifying
enzymes. Proc Natl Acad Sci USA. 107:21499–21504. 2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Akiyama Y, Koda Y, Byeon SJ, Shimada S,
Nishikawaji T, Sakamoto A, Chen Y, Kojima K, Kawano T, Eishi Y, et
al: Reduced expression of SET7/9, a histone mono-methyltransferase,
is associated with gastric cancer progression. Oncotarget.
7:3966–3983. 2016. View Article : Google Scholar :
|
11
|
Song Y, Zhang J, Tian T, Fu X, Wang W, Li
S, Shi T, Suo A, Ruan Z, Guo H and Yao Y: SET7/9 inhibits oncogenic
activities through regulation of Gli-1 expression in breast cancer.
Tumour Biol. 37:9311–9322. 2016. View Article : Google Scholar : PubMed/NCBI
|
12
|
Liu Z, Wu X, Lv J, Sun H and Zhou F:
Resveratrol induces p53 in colorectal cancer through SET7/9. Oncol
Lett. 17:3783–3789. 2019.PubMed/NCBI
|
13
|
Lin G, Liu B, Meng Z, Liu Y, Li X, Wu X,
Zhou Q and Xu K: MiR-26a enhances invasive capacity by suppressing
GSK3β in human lung cancer cells. Exp Cell Res. 352:364–374. 2017.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Song Q, Liu B, Li X, Zhang Q, Cao L, Xu M,
Meng Z, Wu X and Xu K: MiR-26a-5p potentiates metastasis of human
lung cancer cells by regulating ITGβ8-JAK2/STAT3 axis. Biochem
Biophys Res Commun. 501:494–500. 2018. View Article : Google Scholar : PubMed/NCBI
|
15
|
Wang L, Li X, Ren Y, Geng H, Zhang Q, Cao
L, Meng Z, Wu X, Xu M and Xu K: Cancer-associated fibroblasts
contribute to cisplatin resistance by modulating ANXA3 in lung
cancer cells. Cancer Sci. 110:1609–1620. 2019. View Article : Google Scholar : PubMed/NCBI
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
17
|
Wang H, Wang L, Cao L, Zhang Q, Song Q,
Meng Z, Wu X and Xu K: Inhibition of autophagy potentiates the
anti-metastasis effect of phenethyl isothiocyanate through
JAK2/STAT3 pathway in lung cancer cells. Mol Carcinog. 57:522–535.
2018. View
Article : Google Scholar
|
18
|
Chen Y, Yang S, Hu J, Yu C, He M and Cai
Z: Increased expression of SETD7 promotes cell proliferation by
regulating cell cycle and indicates poor prognosis in
hepatocellular carcinoma. PLoS One. 11:e01549392016. View Article : Google Scholar : PubMed/NCBI
|
19
|
Salz T, Deng C, Pampo C, Siemann D, Qiu Y,
Brown K and Huang S: Histone methyltransferase hSETD1A is a novel
regulator of metastasis in breast cancer. Mol Cancer Res.
13:461–469. 2015. View Article : Google Scholar
|
20
|
Welch DR and Hurst DR: Defining the
hallmarks of metastasis. Cancer Res. 79:3011–3027. 2019. View Article : Google Scholar : PubMed/NCBI
|
21
|
Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou
X, Ma H, Wei D and Sun S: The role of JAK/STAT signaling pathway
and its inhibitors in diseases. Int Immunopharmacol. 80:1062102020.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Fu L, Wu H, Cheng SY, Gao D, Zhang L and
Zhao Y: Set7 mediated Gli3 methylation plays a positive role in the
activation of Sonic Hedgehog pathway in mammals. Elife. 5:pii:
e15690. 2016. View Article : Google Scholar
|
23
|
Lezina L, Aksenova V, Ivanova T, Purmessur
N, Antonov AV, Tentler D, Fedorova O, Garabadgiu AV, Talianidis I,
Melino G and Barlev NA: KMTase Set7/9 is a critical regulator of
E2F1 activity upon genotoxic stress. Cell Death Differ.
21:1889–1899. 2014. View Article : Google Scholar : PubMed/NCBI
|
24
|
Gu Y, Wang Y, Wang X, Gao L, Yu W and Dong
WF: Opposite effects of SET7/9 on apoptosis of human acute myeloid
leukemia cells and lung cancer cells. J Cancer. 8:2069–2078. 2017.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Shen C, Wang D, Liu X, Gu B, Du Y, Wei FZ,
Cao LL, Song B, Lu X, Yang Q, et al: SET7/9 regulates cancer cell
proliferation by influencing β-catenin stability. FASEB J.
29:4313–4323. 2015. View Article : Google Scholar : PubMed/NCBI
|
26
|
Gu Y, Wang X, Liu H, Li G, Yu W and Ma Q:
SET7/9 promotes hepatocellular carcinoma progression through
regulation of E2F1. Oncol Rep. 40:1863–1874. 2018.PubMed/NCBI
|
27
|
Zhang Y, Liu J, Lin J, Zhou L, Song Y, Wei
B, Luo X, Chen Z, Chen Y, Xiong J, et al: The transcription factor
GATA1 and the histone methyltransferase SET7 interact to promote
VEGF-mediated angiogenesis and tumor growth and predict clinical
outcome of breast cancer. Oncotarget. 7:9859–9875. 2016.PubMed/NCBI
|
28
|
Wu W, Gao H, Li X, Peng S, Yu J, Liu N,
Zhan G, Zhu Y, Wang K and Guo X: β-hCG promotes epithelial ovarian
cancer metastasis through ERK/MMP2 signaling pathway. Cell Cycle.
18:46–59. 2019. View Article : Google Scholar
|
29
|
Wang X, Yang B, She Y and Ye Y: The lncRNA
TP73-AS1 promotes ovarian cancer cell proliferation and metastasis
via modulation of MMP2 and MMP9. J Cell Biochem. 119:7790–7799.
2018. View Article : Google Scholar : PubMed/NCBI
|
30
|
Zhao L, Liu L, Dong Z and Xiong J: miR-149
suppresses human non-small cell lung cancer growth and metastasis
by inhibiting the FOXM1/cyclin D1/MMP2 axis. Oncol Rep.
38:3522–3530. 2017.PubMed/NCBI
|
31
|
Lai YJ, Yu WN, Kuo SC, Ho CT, Hung CM, Way
TD and Chen CT: CSC-3436 inhibits TWIST-induced
epithelial-mesenchymal transition via the suppression of
Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma. J
Cell Physiol. 234:9118–9129. 2019. View Article : Google Scholar
|
32
|
Patra K, Jana S, Sarkar A, Mandal DP and
Bhattacharjee S: The inhibition of hypoxia-induced angiogenesis and
metastasis by cinnamaldehyde is mediated by decreasing HIF-1α
protein synthesis via PI3K/Akt pathway. Biofactors. 45:401–415.
2019. View Article : Google Scholar : PubMed/NCBI
|
33
|
Li Y, Bai M, Xu Y, Zhao W, Liu N and Yu J:
TPPP3 promotes cell proliferation, invasion and tumor metastasis
via STAT3/Twist1 pathway in non-small-cell lung carcinoma. Cell
Physiol Biochem. 50:2004–2016. 2018. View Article : Google Scholar
|
34
|
Hsu MC, Pan MR and Hung WC: Two birds, one
stone: Double hits on tumor growth and lymphangiogenesis by
targeting vascular endothelial growth factor receptor 3. Cells.
8:E2702019. View Article : Google Scholar : PubMed/NCBI
|
35
|
Zhang H, Ma RR, Wang XJ, Su ZX, Chen X,
Shi DB, Guo XY, Liu HT and Gao P: KIF26B, a novel oncogene,
promotes proliferation and metastasis by activating the VEGF
pathway in gastric cancer. Oncogene. 36:5609–5619. 2017. View Article : Google Scholar : PubMed/NCBI
|
36
|
Zhou W, Wu Y, Pan M, Liu D and Liu B:
Proliferation and migration of lung cancer could be inhibited by
oxymatrine through the regulation for miR-520/VEGF. Am J Chin Med.
47:865–878. 2019. View Article : Google Scholar : PubMed/NCBI
|
37
|
An YX, Shang YJ, Xu ZW, Zhang QC, Wang Z,
Xuan WX and Zhang XJ: STAT3-induced long noncoding RNA LINC00668
promotes migration and invasion of non-small cell lung cancer via
the miR-193a/KLF7 axis. Biomed Pharmacother. 116:1090232019.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Jin Z, Li H, Hong X, Ying G, Lu X, Zhuang
L and Wu S: TRIM14 promotes colorectal cancer cell migration and
invasion through the SPHK1/STAT3 pathway. Cancer Cell Int.
18:2022018. View Article : Google Scholar : PubMed/NCBI
|
39
|
He N, Kong Y, Lei X, Liu Y, Wang J, Xu C,
Wang Y, Du L, Ji K, Wang Q, et al: MSCs inhibit tumor progression
and enhance radiosensitivity of breast cancer cells by
down-regulating Stat3 signaling pathway. Cell Death Dis.
9:10262018. View Article : Google Scholar : PubMed/NCBI
|
40
|
Chong PSY, Chng WJ and de Mel S: STAT3: A
promising therapeutic target in multiple myeloma. Cancers (Basel).
11:E7312019. View Article : Google Scholar
|
41
|
Qin JJ, Yan L, Zhang J and Zhang WD: STAT3
as a potential therapeutic target in triple negative breast cancer:
A systematic review. J Exp Clin Cancer Res. 38:1952019. View Article : Google Scholar : PubMed/NCBI
|